British Journal of Dermatology
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
498 - Real-world use and effectiveness of upadacitinib in adults and adolescents with atopic dermatitis: preliminary analysis of the real-world multicountry AD-VISE study
2024
-
321 Cancer risk with topical pimecrolimus and tacrolimus for atopic dermatitis: systematic review and Bayesian meta-analysis
2023
-
Psoriasis, sleep and interleukin-17: is it a reality or just a dream?
2014
-
Nonmelanoma skin cancer in Canada
2014
-
Nonmelanoma skin cancer in Canada
2014
-
Narrowband ultraviolet (UV) B and psoralen UVA therapy in the treatment of mycosis fungoides: a retrospective study
2007
-
Failure of scabies treatment: a systematic review and meta-analysis.
190:163-173.
2024
-
Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse).
189:540-552.
2023
-
Granzyme K contributes to endothelial microvascular damage and leakage during skin inflammation.
189:279-291.
2023
-
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.
188:22-31.
2023
-
Clinical practice guidelines for psoriasis: which ones are the best?.
187:136-137.
2022
-
Targeting the opioid pathway for the treatment of chronic kidney disease‐associated pruritus: a systematic review and meta‐analysis of randomized controlled trials.
186:575-577.
2022
-
Integrated safety analysis of treatment‐emergent eczematous reactions in patients with moderate‐to‐severe psoriasis treated with ixekizumab, etanercept and ustekinumab.
185:865-867.
2021
-
Reporting of randomized controlled trial abstracts in dermatology journals according to CONSORT guidelines.
185:673-675.
2021
-
A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial*.
184:1047-1058.
2021
-
A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial.
182:1348-1358.
2020
-
Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid‐sparing effect.
182:1111-1119.
2020
-
ACNE‐Q.
181:e165-e165.
2019
-
Development of a new patient‐reported outcome measure to evaluate treatments for acne and acne scarring: the
ACNE
‐Q.
181:1207-1215.
2019
-
The ACNE‐Q.
181:e153-e153.
2019
-
Granulocyte–macrophage colony‐stimulating factor (
GM
‐
CSF
) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti‐
GM
‐
CSF
monoclonal antibody.
180:1352-1360.
2019
-
The
FACE
‐Q Skin Cancer Module addresses post‐resection aesthetic and quality of life outcomes.
180:953-954.
2019
-
FACE-Q Skin Cancer Module for measuring patient-reported outcomes following facial skin cancer surgery.
179:88-94.
2018
-
FACE-Q Skin Cancer Module: appearance satisfaction and QoL.
179:e70-e70.
2018
-
FACE-Q皮肤癌模块:外观满意度和QoL.
179:e84-e84.
2018
-
Survival of the fittest.
178:328-329.
2018
-
Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice.
177:1495-1502.
2017
-
Biosimilars for psoriasis: clinical studies to determine similarity.
177:23-33.
2017
-
Image Gallery: A rare abscess-like presentation of Langerhans cell histiocytosis.
176:e33-e33.
2017
-
Major psychological complications and decreased health-related quality of life among survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis.
175:422-424.
2016
-
Biosimilars for psoriasis: preclinical analytical assessment to determine similarity.
174:282-286.
2016
-
Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).
172:484-493.
2015
-
A treatment for severe nodular acne: a randomized investigator-blinded, controlled, noninferiority trial comparing fixed-dose adapalene/benzoyl peroxide plus doxycycline vs. oral isotretinoin.
171:1508-1516.
2014
-
Protection afforded by controlled application of a barrier cream: a study in a workplace setting.
171:813-818.
2014
-
Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial.
158:1083-1093.
2008
-
Atopic eczema and the home environment.
145:730-736.
2001
-
Is there a geographical variation in eczema prevalence in the U.K.? Evidence from the 1958 British birth cohort study.
142:712-720.
2000
-
The quality of life in acne: a comparison with general medical conditions using generic questionnaires.
140:672-676.
1999
-
The effectiveness of acne treatment: an assessment by patients of the outcome of therapy.
137:563-567.
1997
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)